- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05868486
Analiza obrazowania metodą rezonansu magnetycznego całego ciała i płynnej biopsji w celu wczesnego wykrywania raka u pacjentów z silnym wywiadem rodzinnym w kierunku raka
MRI całego ciała i płynna biopsja do wczesnego wykrywania raka
This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.
Przegląd badań
Status
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To assess the acceptability of the approach of LB and WBM.
SECONDARY OBJECTIVES:
I. Determine the prevalence of WBM findings requiring additional imaging or invasive testing.
II. Determine the effect of germline testing, LB, and WBM on psychological distress and health-related quality of life (HR-QOL) at 6 months after testing compared with baseline.
EXPLORATORY OBJECTIVE:
I. Determine correlation between high-risk LB findings and cancer detected on WBM.
OUTLINE: This is an observational study.
Patients undergo WBM without contrast, blood sample collection for liquid biopsy, and complete surveys on study. Germline testing may also be performed on blood sample collected as standard of care or using the Precision Medicine protocol (Institutional Review Board [IRB] 96144).
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Wczesna faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
Duarte, California, Stany Zjednoczone, 91010
- City of Hope Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age >= 50 years, or age within 10 years of first degree relative with cancer at age of diagnosis (as long as age is >= 18)
- Have a strong family history of cancer ( >= 2 first-degree relatives with cancer, one first and second degree relative with cancer in one lineage (side of family), or at least three first or second degree relatives with cancer in one lineage (side of the family). Non-melanoma skin cancer excluded from family history eligibility
- Have a family history of early-onset cancer (age >40) in at least one first-degree relative
- Willing to have 50 mL of blood (approximately 3.5 tablespoons) drawn (40 ml if germline testing already performed)
- Able to undergo MRI (no implants, metal, or claustrophobia that would preclude MRI)
- Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer
- Positron emission tomography/computed tomography (PET/CT) or other whole body imaging modality (including combination of CT chest and abdomen) within 3 years
- No signs/symptoms of possible cancer (e.g. hemoptysis, breast mass, blood per rectum, unexplained weight loss)
- Willing to undergo standard of care genetic counseling and germline testing, or has already undergone genetic counseling and germline testing
- Documented informed consent of the participant
Exclusion Criteria:
- Unable to provide informed consent
- Contraindications to MRI (implants, metal, or claustrophobia that would preclude MRI)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Ekranizacja
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Whole Body MRI and Liquid Biopsy
Patients undergo WBM without contrast and blood sample collection for liquid biopsy |
Undergo blood sample collection
Inne nazwy:
Complete surveys Undergo germline testing
Inne nazwy:
Undergo liquid biopsy testing
Inne nazwy:
Undergo whole body MRI without contrast
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging (WBM)
Ramy czasowe: Up to 6 months after WBM
|
Acceptability, as measured by the survey question "How satisfied are you with the research study overall?" and is defined as a score of 4 ("moderately acceptable) or 5 ("highly acceptable"). |
Up to 6 months after WBM
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Prevalence of WBM findings requiring additional imaging or invasive testing
Ramy czasowe: Up to 6 months after WBM
|
Prevalence of WBM findings requiring additional imaging or invasive testing, described as a per participant percentage. |
Up to 6 months after WBM
|
|
Psychological distress (Germline testing)A
Ramy czasowe: Up to 6 months after WBM
|
The effect of germline testing on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (Germline testing)B
Ramy czasowe: Up to 6 months after WBM
|
The effect of germline testing on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (Liquid Biopsy)A
Ramy czasowe: Up to 6 months after WBM
|
The effect of LB on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (Liquid Biopsy)B
Ramy czasowe: Up to 6 months after WBM
|
The effect of LB on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (WBM)A
Ramy czasowe: Up to 6 months after WBM
|
The effect of Whole Body MRI on Psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (WBM)B
Ramy czasowe: Up to 6 months after WBM
|
The effect of Whole Body MRI on Psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Health Related Quality of Life (HRQOL/Germline)
Ramy czasowe: Up to 6 months after WBM
|
The effect of germline testing on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Health Related Quality of Life (HRQOL/LB)
Ramy czasowe: Up to 6 months after WBM
|
The effect of LB on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Health Related Quality of Life (HRQOL/WBM)
Ramy czasowe: Up to 6 months after WBM
|
The effect of WBM on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Correlation between high-risk liquid biopsy findings and cancer detected on WBM
Ramy czasowe: Up to 6 months after WBM
|
Liquid biopsy (LB) test sensitivity and specificity calculated by comparing the LB results with the WBM results, with WBM results considered the gold standard. Confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy examined. Results reported with their corresponding 95% confidence intervals. |
Up to 6 months after WBM
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Dan Raz, City of Hope Medical Center
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Techniki cytologiczne
- Biopsja
- Cytodiagnoza
- Działania farmakologiczne
- Działania i zastosowania chemiczne
- Usługi zdrowotne
- Zakłady opieki zdrowotnej i usługi
- Community Health Services
- Pobieżne usługi zdrowotne
- Dyscypliny i działania behawioralne
- Specjalne zastosowania chemikaliów
- Usługi zdrowia psychicznego
- Techniki genetyczne
- Usługi genetyczne
- Usługi diagnostyczne
- Diagnostyczne zastosowania chemikaliów
- Biopsja płynna
- Prowadzenie okazów
- Testy genetyczne
- Doradztwo
- Contrast Media
Inne numery identyfikacyjne badania
- 21574
- P30CA033572 (Grant/umowa NIH USA)
- 21574 (Inny identyfikator: City of Hope Medical Center)
- NCI-2022-01829 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .